Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenosine monophosphate activated protein kinase gamma 3 (AMPK γ3) is a non-catalytic regulatory subunit of the AMP-activated protein kinase (AMPK) complex, encoded by the PRKAG3 gene. AMPK is a heterotrimeric enzyme that acts as an energy sensor. The γ3 isoform is predominantly expressed in skeletal muscle and plays a key role in regulating muscle energy metabolism. Mutations in PRKAG3 are linked to altered insulin sensitivity and glycogen storage. AMPKγ3 is a therapeutic target for metabolic disorders such as type 2 diabetes.
Activation of AMPK, stimulation of glucose uptake via GLUT4 translocation, enhancement of fatty acid oxidation, inhibition of cholesterol synthesis, suppression of gluconeogenesis, inhibition of mTORC1 signaling
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenosine monophosphate activated protein kinase gamma 3 (AMPK γ3).